Alpha-carboxynucleoside phosphonates: Direct-acting inhibitors of viral DNA polymerases

Jan Balzarini, Alan Ford, Nuala M. Maguire, Jubi John, Kalyan Das, Edward Arnold, Wim Dehaen, Anita Maguire

Research output: Contribution to journalReview article

Abstract

Acyclic nucleoside phosphonates represent a well-defined class of clinically used nucleoside analogs. All acyclic nucleoside phosphonates need intracellular phosphorylation before they can bind viral DNA polymerases. Recently, a novel class of alpha-carboxynucleoside phosphonates have been designed to mimic the natural 2′-deoxynucleotide 5′-triphosphate substrates of DNA polymerases. They contain a carboxyl group in the phosphonate moiety linked to the nucleobase through a cyclic or acyclic bridge. Alpha-carboxynucleoside phosphonates act as viral DNA polymerase inhibitors without any prior requirement of metabolic conversion. Selective inhibitory activity against retroviral reverse transcriptase and herpesvirus DNA polymerases have been demonstrated. These compounds have a unique mechanism of inhibition of viral DNA polymerases, and provide possibilities for further modifications to optimize and fine tune their antiviral DNA polymerase spectrum.

Original languageEnglish (US)
Pages (from-to)137-154
Number of pages18
JournalFuture Medicinal Chemistry
Volume11
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nucleic Acid Synthesis Inhibitors
Organophosphonates
Viral DNA
DNA-Directed DNA Polymerase
Nucleosides
Herpesviridae
RNA-Directed DNA Polymerase
Antiviral Agents
Phosphorylation

Cite this

Balzarini, Jan ; Ford, Alan ; Maguire, Nuala M. ; John, Jubi ; Das, Kalyan ; Arnold, Edward ; Dehaen, Wim ; Maguire, Anita. / Alpha-carboxynucleoside phosphonates : Direct-acting inhibitors of viral DNA polymerases. In: Future Medicinal Chemistry. 2019 ; Vol. 11, No. 2. pp. 137-154.
@article{be2aacd07a4b44018fe8e35dfd79ee56,
title = "Alpha-carboxynucleoside phosphonates: Direct-acting inhibitors of viral DNA polymerases",
abstract = "Acyclic nucleoside phosphonates represent a well-defined class of clinically used nucleoside analogs. All acyclic nucleoside phosphonates need intracellular phosphorylation before they can bind viral DNA polymerases. Recently, a novel class of alpha-carboxynucleoside phosphonates have been designed to mimic the natural 2′-deoxynucleotide 5′-triphosphate substrates of DNA polymerases. They contain a carboxyl group in the phosphonate moiety linked to the nucleobase through a cyclic or acyclic bridge. Alpha-carboxynucleoside phosphonates act as viral DNA polymerase inhibitors without any prior requirement of metabolic conversion. Selective inhibitory activity against retroviral reverse transcriptase and herpesvirus DNA polymerases have been demonstrated. These compounds have a unique mechanism of inhibition of viral DNA polymerases, and provide possibilities for further modifications to optimize and fine tune their antiviral DNA polymerase spectrum.",
author = "Jan Balzarini and Alan Ford and Maguire, {Nuala M.} and Jubi John and Kalyan Das and Edward Arnold and Wim Dehaen and Anita Maguire",
year = "2019",
month = "1",
day = "1",
doi = "https://doi.org/10.4155/fmc-2018-0324",
language = "English (US)",
volume = "11",
pages = "137--154",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "2",

}

Balzarini, J, Ford, A, Maguire, NM, John, J, Das, K, Arnold, E, Dehaen, W & Maguire, A 2019, 'Alpha-carboxynucleoside phosphonates: Direct-acting inhibitors of viral DNA polymerases' Future Medicinal Chemistry, vol. 11, no. 2, pp. 137-154. https://doi.org/10.4155/fmc-2018-0324

Alpha-carboxynucleoside phosphonates : Direct-acting inhibitors of viral DNA polymerases. / Balzarini, Jan; Ford, Alan; Maguire, Nuala M.; John, Jubi; Das, Kalyan; Arnold, Edward; Dehaen, Wim; Maguire, Anita.

In: Future Medicinal Chemistry, Vol. 11, No. 2, 01.01.2019, p. 137-154.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Alpha-carboxynucleoside phosphonates

T2 - Direct-acting inhibitors of viral DNA polymerases

AU - Balzarini, Jan

AU - Ford, Alan

AU - Maguire, Nuala M.

AU - John, Jubi

AU - Das, Kalyan

AU - Arnold, Edward

AU - Dehaen, Wim

AU - Maguire, Anita

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Acyclic nucleoside phosphonates represent a well-defined class of clinically used nucleoside analogs. All acyclic nucleoside phosphonates need intracellular phosphorylation before they can bind viral DNA polymerases. Recently, a novel class of alpha-carboxynucleoside phosphonates have been designed to mimic the natural 2′-deoxynucleotide 5′-triphosphate substrates of DNA polymerases. They contain a carboxyl group in the phosphonate moiety linked to the nucleobase through a cyclic or acyclic bridge. Alpha-carboxynucleoside phosphonates act as viral DNA polymerase inhibitors without any prior requirement of metabolic conversion. Selective inhibitory activity against retroviral reverse transcriptase and herpesvirus DNA polymerases have been demonstrated. These compounds have a unique mechanism of inhibition of viral DNA polymerases, and provide possibilities for further modifications to optimize and fine tune their antiviral DNA polymerase spectrum.

AB - Acyclic nucleoside phosphonates represent a well-defined class of clinically used nucleoside analogs. All acyclic nucleoside phosphonates need intracellular phosphorylation before they can bind viral DNA polymerases. Recently, a novel class of alpha-carboxynucleoside phosphonates have been designed to mimic the natural 2′-deoxynucleotide 5′-triphosphate substrates of DNA polymerases. They contain a carboxyl group in the phosphonate moiety linked to the nucleobase through a cyclic or acyclic bridge. Alpha-carboxynucleoside phosphonates act as viral DNA polymerase inhibitors without any prior requirement of metabolic conversion. Selective inhibitory activity against retroviral reverse transcriptase and herpesvirus DNA polymerases have been demonstrated. These compounds have a unique mechanism of inhibition of viral DNA polymerases, and provide possibilities for further modifications to optimize and fine tune their antiviral DNA polymerase spectrum.

UR - http://www.scopus.com/inward/record.url?scp=85060617033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060617033&partnerID=8YFLogxK

U2 - https://doi.org/10.4155/fmc-2018-0324

DO - https://doi.org/10.4155/fmc-2018-0324

M3 - Review article

VL - 11

SP - 137

EP - 154

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 2

ER -